Previous close | 8.96 |
Open | 8.96 |
Bid | 10.30 |
Ask | 10.80 |
Strike | 17.50 |
Expiry date | 2025-01-17 |
Day's range | 8.96 - 8.96 |
Contract range | N/A |
Volume | |
Open interest | 2 |
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p.m. CEST/Noon EDT CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.